In conclusion, the addition of palbociclib to endocrine therapy in advanced HR-positive, HER2-negative breast cancer results in dose modifications in 38.0% of patients due to AEs with 18.4% requiring subsequent dose changes. Here, ERBB2 is linked to breast carcinoma.